AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17379842 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestimide (3000 mg/d)
Number of subjects: 12
Study 17379842 — intervention group
Group type: COMPARATOR
Intervention: Normocholesterolemic controls (11 age-matched volunteers)
Number of subjects: 12
Study 16236837 — intervention group
Group type: EXPERIMENTAL
Intervention: Roaring Adventures of Puff asthma education program
Number of subjects: 256
Study 16236837 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study 12193911 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (1 to 4 mU/min) and placebo intravaginal misoprostol
Number of subjects: 0
Study 12193911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microg, repeated at 4 hourly intervals if <3 uterine contractions per 10 minutes)
Number of subjects: 0
Study 12193911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 0
Study 12193911 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 0
Study 10192667 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-based Asthma Observation Unit (AOU)
Number of subjects: 163
Study 10192667 — intervention group
Group type: COMPARATOR
Intervention: Inpatient hospitalization (control group)
Number of subjects: 163
Study 8520442 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/day for 7 days)
Number of subjects: 29
Study 8520442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2361796 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aluminium chloride hexahydrate 20% W/W ethanol (ACH) applied daily for 4 weeks
Number of subjects: 12
Study 2361796 — intervention group
Group type: COMPARATOR
Intervention: Untreated palms (control)
Number of subjects: 12
Study 415471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride 300 microgram orally
Number of subjects: 0
Study 415471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride 100 microgram orally
Number of subjects: 0
Study 415471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride 200 microgram orally
Number of subjects: 0
Study 415471 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride 50 mg injection
Number of subjects: 0
Study 30444276 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz Peripheral Nerve Stimulation (PNS) for 4 hours
Number of subjects: 69
Study 30444276 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz Peripheral Nerve Stimulation (PNS) for 2 hours
Number of subjects: 69
Study 30444276 — intervention group
Group type: COMPARATOR
Intervention: Control (PNS turned OFF)
Number of subjects: 69
Study 30444276 — intervention group
Group type: COMPARATOR
Intervention: 10 kHz Spinal Cord Stimulation (SCS)
Number of subjects: 69
Study 27696656 — intervention group
Group type: EXPERIMENTAL
Intervention: Single reinduction course
Number of subjects: 1366
Study 27696656 — intervention group
Group type: EXPERIMENTAL
Intervention: Double reinduction courses
Number of subjects: 1366
Study 27696656 — intervention group
Group type: COMPARATOR
Intervention: Triple intrathecal therapy without cranial radiation (CrRT)
Number of subjects: 1366
Study 27696656 — intervention group
Group type: EXPERIMENTAL
Intervention: MLL or BCR-ABL1 positive patients
Number of subjects: 1366
Study 25680375 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy (specific agents not detailed)
Number of subjects: 0
Study 25680375 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 23640544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) delivered by a psychologist plus treatment as usual (education, reassurance, and symptom management strategies)
Number of subjects: 28
Study 23640544 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (education, reassurance, and symptom management strategies)
Number of subjects: 28
Study 21533329 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural treatment
Number of subjects: 54
Study 21533329 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 19387331 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 26
Study 19387331 — intervention group
Group type: COMPARATOR
Intervention: Sham-stimulated control
Number of subjects: 26
Study 17967668 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg)
Number of subjects: 120
Study 17967668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (0.5 mg/kg)
Number of subjects: 120
Study 17967668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15090770 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908/ritonavir (908/r) 1400 mg/200 mg, once daily (q.d.)
Number of subjects: 649
Study 15090770 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir 1250 mg, twice daily (b.i.d.)
Number of subjects: 649
Study 11274623 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, all given four times daily for one week)
Number of subjects: 400
Study 11274623 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg daily for six months)
Number of subjects: 400
Study 9636912 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (n = 11)
Number of subjects: 21
Study 9636912 — intervention group
Group type: COMPARATOR
Intervention: Placebo circuits (n = 10)
Number of subjects: 21
Study 7872715 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 27
Study 7872715 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 27
Study 7872715 — intervention group
Group type: COMPARATOR
Intervention: Control Ovaries
Number of subjects: 27
Study 7872715 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant Tumour Tissue
Number of subjects: 27
Study 7872715 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF or IGF-1
Number of subjects: 27
Study 2835427 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 39
Study 2835427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 39
Study 2835427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28503741 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma injection
Number of subjects: 30
Study 28503741 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study 28827250 — intervention group
Group type: COMPARATOR
Intervention: Short document
Number of subjects: 460
Study 28827250 — intervention group
Group type: COMPARATOR
Intervention: Structured response
Number of subjects: 460
Study 26301701 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 mg/d
Number of subjects: 353
Study 26301701 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 353
Study 23178320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine (LN, 0.4 mg/g)
Number of subjects: 0
Study 23178320 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine (HN, 11.4-12.8 mg/g)
Number of subjects: 0
Study 23178320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate nicotine (IN, 5.7-5.8 mg/g)
Number of subjects: 0
Study 21951091 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered Wallstent (CWS)
Number of subjects: 113
Study 21951091 — intervention group
Group type: COMPARATOR
Intervention: DoubleLayer stent (DLS)
Number of subjects: 113
Study 18297436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment schedule (three treatment sessions per week for the first 2 weeks)
Number of subjects: 30
Study 18297436 — intervention group
Group type: COMPARATOR
Intervention: Original treatment schedule (weekly treatment)
Number of subjects: 30
Study 16571158 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalgae oil (0.94 g DHA/d)
Number of subjects: 114
Study 16571158 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 114
Study 15289837 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP (80 mg/m(2)) as a continuous 2‐h intravenous infusion on day 1 and 5‐FU (700 mg/m(2)) as a continuous intravenous infusion on days 2‐5 (Group A)
Number of subjects: 74
Study 15289837 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU (700 mg/m(2)) as a continuous intravenous infusion on days 1‐4, followed by CDDP (80 mg/m(2)) as a continuous 2‐h intravenous infusion on day 5 (Group B)
Number of subjects: 74
Study 15289837 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP before 5‐FU
Number of subjects: 74
Study 15289837 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU before CDDP
Number of subjects: 74
Study 15289837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study 11762807 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine at 60 mg/m2/week for the first three administrations, then increased to 80 mg/m2/week
Number of subjects: 115
Study 11762807 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) vinorelbine at 30 mg/m2/week
Number of subjects: 115
Study 8996153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (CT) plus radiotherapy (RT): cisplatin 75 mg/m2 on day 1 and fluorouracil (5FU) 1,000 mg/m2/d on days 1 to 4 every 4 weeks with RT and every 3 weeks post‐RT.
Number of subjects: 123
Study 8996153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (CT) plus radiotherapy (RT): additional patients treated with the same combined therapy.
Number of subjects: 123
Study 8996153 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone: 64 Gy RT.
Number of subjects: 123
Study 8435253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam 20 mg
Number of subjects: 10
Study 8435253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3315513 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin bolus at 2300 h (2.1 +/- 0.2 U)
Number of subjects: 9
Study 3315513 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin bolus at 0100 h (after reactivating the pump at 1.05 +/- 0.11 U/h)
Number of subjects: 9
Study 3315513 — intervention group
Group type: COMPARATOR
Intervention: Reference control group (pump functioning normally throughout the night)
Number of subjects: 9
Study 29596158 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) combined with exercise therapy (ET)
Number of subjects: 185
Study 29596158 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy (ET) alone
Number of subjects: 185
Study 27576085 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR-instructor-course (4h preparatory seminar and teaching session in BLS for school children)
Number of subjects: 80
Study 27576085 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 24461109 — intervention group
Group type: COMPARATOR
Intervention: Pasireotide 600 μg sc bid alone
Number of subjects: 90
Study 24461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Metformin 500 mg po bid
Number of subjects: 90
Study 24461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Nateglinide 60 mg po tid
Number of subjects: 90
Study 24461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Vildagliptin 50 mg po bid
Number of subjects: 90
Study 24461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Liraglutide 0.6 mg sc qd
Number of subjects: 90
Study 24461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Nateglinide
Number of subjects: 90
Study 24461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Metformin
Number of subjects: 90
Study 24461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Liraglutide
Number of subjects: 90
Study 24461109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Vildagliptin
Number of subjects: 90
Study 22648092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (330 ml/day for four weeks)
Number of subjects: 51
Study 22648092 — intervention group
Group type: COMPARATOR
Intervention: Control drink (330 ml/day for four weeks)
Number of subjects: 51
Study 20099369 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of ebastine plus 120 mg of pseudoephedrine complex
Number of subjects: 0
Study 18184907 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized lifestyle intervention
Number of subjects: 522
Study 18184907 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 522
Study 16448783 — intervention group
Group type: EXPERIMENTAL
Intervention: FTND-ST
Number of subjects: 42
Study 12551863 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg BID)
Number of subjects: 14
Study 12551863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10406065 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PTCA (percutaneous transluminal coronary angioplasty)
Number of subjects: 0
Study 10406065 — intervention group
Group type: COMPARATOR
Intervention: Routine IABP insertion during primary PTCA
Number of subjects: 0
Study 10406065 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 0
Study 10406065 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive pharmacotherapy with potent antiplatelet agents
Number of subjects: 0
Study 7574856 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 20 mg once daily
Number of subjects: 23
Study 7574856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2625539 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening testing (15:00 h)
Number of subjects: 24
Study 2625539 — intervention group
Group type: COMPARATOR
Intervention: Morning testing (10:00 h)
Number of subjects: 24
Study 2625539 — intervention group
Group type: EXPERIMENTAL
Intervention: CFF (Critical Flicker Fusion)
Number of subjects: 24
Study 1058542 — intervention group
Group type: EXPERIMENTAL
Intervention: Four times repeated spray application
Number of subjects: 21
Study 1058542 — intervention group
Group type: COMPARATOR
Intervention: Antiseptics added to the spray
Number of subjects: 21
Study 31933439 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal attention condition
Number of subjects: 12
Study 31933439 — intervention group
Group type: COMPARATOR
Intervention: Nonverbal attention condition
Number of subjects: 12
Study 31002426 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 1
Study 31002426 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 1
Study 28364475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavioral intervention
Number of subjects: 380
Study 28364475 — intervention group
Group type: COMPARATOR
Intervention: Attention control arm
Number of subjects: 380
Study 24997757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol and gestodene patch (delivering low doses equivalent to 0.02 mg EE and 0.06 mg GSD) applied once weekly for 3 weeks
Number of subjects: 0
Study 24997757 — intervention group
Group type: COMPARATOR
Intervention: CYP3A4 inhibitors (erythromycin and ketoconazole) administered concurrently with the patch
Number of subjects: 0
Study 24997757 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A4 substrate) administered alone and after 3 weeks of concurrent patch application
Number of subjects: 0
Study 23351464 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention and optimal medical therapy
Number of subjects: 283
Study 23351464 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 283
Study 21983118 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnidrop
Number of subjects: 27
Study 21983118 — intervention group
Group type: EXPERIMENTAL
Intervention: Optive
Number of subjects: 27
Study 21983118 — intervention group
Group type: COMPARATOR
Intervention: Blu Sal
Number of subjects: 27
Study 19136338 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 48
Study 19136338 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 48
Study 17715456 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements
Number of subjects: 15
Study 17715456 — intervention group
Group type: COMPARATOR
Intervention: Blinking patterns
Number of subjects: 15
Study 15089890 — intervention group
Group type: EXPERIMENTAL
Intervention: Licofelone 200 mg b.i.d. (n = 30)
Number of subjects: 121
Study 15089890 — intervention group
Group type: EXPERIMENTAL
Intervention: Licofelone 400 mg b.i.d. (n = 30)
Number of subjects: 121
Study 15089890 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg b.i.d. (n = 30)
Number of subjects: 121
Study 15089890 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 121
Study 15089890 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg b.i.d.
Number of subjects: 121
Study 15089890 — intervention group
Group type: EXPERIMENTAL
Intervention: Licofelone 200 mg b.i.d.
Number of subjects: 121
Study 15089890 — intervention group
Group type: EXPERIMENTAL
Intervention: Licofelone 400 mg b.i.d.
Number of subjects: 121
Study 15089890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 15089890 — intervention group
Group type: EXPERIMENTAL
Intervention: Licofelone 200 mg b.i.d. or Naproxen therapy
Number of subjects: 121
Study 15089890 — intervention group
Group type: EXPERIMENTAL
Intervention: Licofelone or Naproxen therapy
Number of subjects: 121
Study 11455257 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg per day
Number of subjects: 81
Study 11455257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1 g twice daily
Number of subjects: 81
Study 11455257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 81
Study 11455257 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 81
Study 11455257 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MMF and AZA
Number of subjects: 81
Study 9726387 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., clarithromycin 250 mg b.d.)
Number of subjects: 262
Study 9726387 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Number of subjects: 262
Study 9726387 — intervention group
Group type: EXPERIMENTAL
Intervention: LCM (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Number of subjects: 262
Study 9726387 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM (omeprazole 20 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Number of subjects: 262
Study 8070443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (3 mg/kg/day)
Number of subjects: 46
Study 8070443 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (7 mg/kg/day)
Number of subjects: 46
Study 3639930 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula samples
Number of subjects: 95
Study 3639930 — intervention group
Group type: COMPARATOR
Intervention: No infant formula samples (Control)
Number of subjects: 95
Study 31912937 — intervention group
Group type: EXPERIMENTAL
Intervention: Milligan's operation
Number of subjects: 151
Study 31912937 — intervention group
Group type: COMPARATOR
Intervention: Ferguson's operation
Number of subjects: 151
Study 30342503 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program related to older people (intervention)
Number of subjects: 124
Study 30342503 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 124
Study 27538992 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicortical plate and screw fixation
Number of subjects: 315
Study 27538992 — intervention group
Group type: COMPARATOR
Intervention: Bicortical plate and screw fixation
Number of subjects: 315
Study 24200256 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated school-wide program focusing on foods and beverages, physical education, classroom-based behavior change and education, and social marketing communication and promotional campaigns.
Number of subjects: 4603
Study 24200256 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 schools, 2296 students).
Number of subjects: 4603
Study 22013105 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg twice daily
Number of subjects: 24
Study 20510523 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure group (≥500 mg/week)
Number of subjects: 321
Study 20510523 — intervention group
Group type: COMPARATOR
Intervention: Moderate exposure group (250-499 mg/week)
Number of subjects: 321
Study 20510523 — intervention group
Group type: COMPARATOR
Intervention: Zero-low exposure group (0-249 mg/week)
Number of subjects: 321
Study 18479659 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 AU/week
Number of subjects: 65
Study 18479659 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 AU/week
Number of subjects: 65
Study 18479659 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 65
Study 18479659 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 65
Study 18479659 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT groups
Number of subjects: 65
Study 20031797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560
Study 20031797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6560
Study 15106805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 242
Study 15106805 — intervention group
Group type: COMPARATOR
Intervention: Coamilozide
Number of subjects: 242
Study 15106805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Coamilozide
Number of subjects: 242
Study 11372922 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox) injections via percutaneous posterior‐lateral approach
Number of subjects: 15
Study 11372922 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox) injections via transnasal fiberoptic approach
Number of subjects: 15